Latest Commercial Operations News

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

Paladin Energy’s 2025 Annual Report reveals a pivotal year marked by operational ramp-up at Namibia’s Langer Heinrich Mine and the strategic acquisition of Fission Uranium in Canada, positioning the company for multi-decade growth amid a tightening uranium market.

Everest Metals has received $150,000 from the Minerals Research Institute of Western Australia to advance rubidium extraction at its Mt Edon project, aiming to establish Australia’s first commercial rubidium industry and reduce reliance on Chinese supply chains.

EML Payments reported a 9% revenue increase and 13% rise in underlying EBITDA for FY25, driven by strategic partnerships and operational transformation. The company sets a steady growth outlook for FY26 despite expected interest revenue headwinds.

Aurelia Metals has reported a robust turnaround in FY25 with a 69% jump in EBITDA and a return to profitability, driven by operational gains at Peak and Federation. The company is advancing key growth projects targeting 40kt copper equivalent production by FY28.

Aurelia Metals Limited has reported a strong turnaround with a $48.9 million net profit for FY25, driven by operational progress at its Federation Mine and the approval of the Great Cobar Project. The company’s strategic focus on base metals growth and sustainability underpins its improved financial and safety performance.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Amaero Ltd reported a 470% revenue surge to $3.8 million for FY2025, driven by expanded production capacity and exclusive supply deals, while continuing to invest heavily in infrastructure and operations, resulting in a $24.4 million loss.